|1.||Rascol, Olivier: 16 articles (03/2014 - 06/2007)|
|2.||Poewe, Werner: 15 articles (01/2014 - 08/2006)|
|3.||Barone, Paolo: 12 articles (01/2014 - 05/2006)|
|4.||Oertel, Wolfgang H: 9 articles (07/2014 - 01/2004)|
|5.||Schapira, Anthony H V: 8 articles (08/2013 - 12/2004)|
|6.||Parkinson Study Group: 8 articles (03/2013 - 10/2000)|
|7.||Koester, Juergen: 8 articles (01/2011 - 01/2005)|
|8.||Ferini-Strambi, Luigi: 7 articles (05/2014 - 12/2003)|
|9.||Manconi, Mauro: 7 articles (05/2014 - 12/2003)|
|10.||Mizuno, Yoshikuni: 7 articles (01/2014 - 10/2003)|
|1.||Parkinson Disease (Parkinson's Disease)
05/01/2005 - "In addition, pramipexole significantly improved the subitems motivation/initiative and depression in a subpopulation with increased Unified Parkinson's Disease Rating Scale I scores at the time of inclusion. "
05/01/2014 - "Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease."
07/11/1997 - "In the present study, pramipexole, a D3-preferring DA agonist effective in treating Parkinson's disease, excited type II anterior CN neurons. "
04/15/2015 - "Intranasal delivery is emerging as a promising alternative for oral or intravenous administration of central nervous system (CNS) drugs, such as pramipexole which is widely used for the treatment of Parkinson's disease. "
01/01/2010 - "Pramipexole extended release: a novel treatment option in Parkinson's disease."
|2.||Restless Legs Syndrome (Restless Legs)
01/01/2010 - "Pramipexole group showed a significant reduction in the International Restless Legs Syndrome Study Group rating scale (IRLS; p=0.0005), a significant improvement in both Patient Global Impression (PGI; p<0.0001) and Clinical Global Impressions (CGI-I; p=0.0488), and a significantly greater mean reduction in the Pittsburgh Sleep Quality Index (PSQI; p=0.0016), when compared with those of placebo group at week 6. Pramipexole is highly efficacious in the reduction of PLMI and in the improvement of subjective severity of RLS and subjective sleep disturbance caused by the disorder."
01/01/2012 - "Of 287 patients in the full analysis set, the pramipexole group showed significant improvement compared with the placebo group in the change of their International Restless Legs Syndrome Study Group Rating Scale of Severity (IRLS) total score from baseline to week 6 after adjustment of centers and baseline characters (-15.87±0.66 vs. -11.35±0.92, p<0.0001) and in the proportion of patients who were "much improved" and "very much improved" when measured by Clinical Global Impressions-Improvement (81.9% vs. 54.3%, p<0.0001). "
04/01/2011 - "Pramipexole is an effective treatment for restless legs syndrome (RLS), but no controlled studies have lasted >12 weeks. "
01/20/2007 - "Fifty-one patients suffering from idiopathic restless legs syndrome underwent monotherapy with pramipexole in daily doses of 0.25 to 1.0 mg. Therapeutic efficacy was evaluated using three tools, i.e. "
07/15/2010 - "A phase III, open-label, long-term clinical study was performed to evaluate the safety and efficacy of pramipexole in a cohort of 141 Japanese patients with primary restless legs syndrome (RLS). "
05/01/2000 - "In another study pramipexole has been shown to be significantly superior to placebo with an improvement in tremor score by 48% (vs. 13% in the placebo group). "
01/01/2015 - "Pramipexole has demonstrated the efficacy in the treatment of persistent tremor and depression in double-blind placebo-controlled trials. "
09/01/1999 - "The patients were drawn from a larger placebo-controlled, double-blind, randomized trial, which was not originally designed to investigate the effect of pramipexole on tremor. "
01/01/2006 - "The main reasons for switching to pramipexole (anti-tremor effect, anti-depressive/anti-anhedonic effect) as given by the physicians at baseline came up to expectations. "
05/01/2005 - "Patients with pronounced resting tremor derived a clear benefit from pramipexole treatment compared with placebo. "
07/01/2004 - "Initial pramipexole treatment resulted in a significant reduction in the risk of developing dyskinesias (24.5% vs 54%; hazard ratio, 0.37; 95% confidence interval [CI], 0.25-0.56; P<.001) and wearing off (47% vs 62.7%; hazard ratio, 0.68; 95% CI, 0.49-0.63; P =.02). "
04/01/2008 - "This review addresses the literature concerning pramipexole's efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances."
01/01/2008 - "Furthermore, in laboratory studies pramipexole has proved to exert neuroprotector effects and its use in clinical practice from the early stages of the disease has been related to a delay in the appearance of motor complications (fluctuations and dyskinesias). "
01/01/2000 - "No significant changes were noted in a dyskinesia rating scale in any of the 4 studies, but dyskinesia as an adverse event was reported more frequently with pramipexole. "
04/01/2014 - "When compared with delayed-start pramipexole, early-start pramipexole induced a higher rotational response (p<0.01), but did not improve limb akinesia, induce dyskinesia nor normalize lesion-induced molecular changes. "
|5.||Bipolar Disorder (Mania)
03/01/2004 - "Pramipexole was a safe and effective antidepressant among patients with bipolar depression. "
03/01/2004 - "The authors conducted a preliminary randomized, placebo-controlled trial to determine the safety and antidepressant efficacy of pramipexole in treatment-resistant bipolar depression. "
11/01/2013 - "The present review aims to provide an updated perspective on the use of adjunctive pramipexole in bipolar depression, taking into account randomized-controlled trials, as well as open naturalistic studies, with a specific focus on the evaluation of acute versus long-term data in terms of effectiveness and tolerability. "
01/01/2012 - "Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction."
01/01/2007 - "Recently published placebo-controlled trials in small patient groups implicate that pramipexole is effective as additional treatment to mood stabilizers in I and II bipolar depression."
|1.||Dopamine Agonists (Dopamine Agonist)
|2.||Levodopa (L Dopa)
|9.||Dopamine Receptors (Dopamine Receptor)
|1.||Activities of Daily Living (ADL)
|2.||Continuous Positive Airway Pressure
|5.||Renal Dialysis (Hemodialysis)